Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

RESTART is a randomised controlled trial for adults surviving spontaneous intracerebral haemorrhage who had taken an antithrombotic drug (i.e. anticoagulant or antiplatelet medication) for the prevention of vaso-occlusive disease before the ICH.

RESTART is testing whether a policy of starting antiplatelet drugs (one or more of aspirin, clopidogrel, or dipyridamole, chosen at investigator's discretion) results in a beneficial net reduction of all serious vascular events over two years compared with a policy of avoiding antiplatelet drugs. RESTART began recruitment in the United Kingdom in May 2013. RESTART is run by a team from the University of Edinburgh, in collaboration with researchers at the University of Dundee, the University of Newcastle-upon-Tyne, and University College London. The trial is now closed.

The Royal Preston Hospital (part of Lancashire Teaching Hospitals) was a recruitment centre for the trial.

Further information about the trial can be found on the RESTART website.